ArticleLung cancer (Amsterdam, Netherlands)2011
Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer.
Article in Lung cancer (Amsterdam, Netherlands), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Soluble immune checkpoints in lung cancer: linking prognostic signatures to immunotherapy response - a meta-analysis.Frontiers in immunology · 2026Pooled it
- Expression patterns of estrogen and androgen receptors in NSCLC patients according to the PD-L1 profile.Frontiers in immunology · 2025Article
- Sex-specific cytokine signatures as predictors of anti-PD1 therapy response in non-small cell lung cancer.Frontiers in immunology · 2025Article
- Estrogen Signals through ERβ in Breast Cancer; What We Have Learned since the Discovery of the Receptor.Receptors (Basel, Switzerland) · 2024Article
- METTL3 drives NSCLC metastasis by enhancing CYP19A1 translation and oestrogen synthesis.Cell & bioscience · 2024Article
- Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer.Frontiers in oncology · 2023Article
- Role of sex and sex hormones in PD-L1 expression in NSCLC: clinical and therapeutic implications.Frontiers in oncology · 2023Review
- Estrogens, Cancer and Immunity.Cancers · 2022Review
- Sex-specific hormone changes during immunotherapy and its influence on survival in metastatic renal cell carcinoma.Cancer immunology, immunotherapy : CII · 2021Article
- Upregulation of estrogen receptor beta protein but not mRNA predicts poor prognosis and may be associated with enhanced translation in non-small cell lung cancer: a systematic review and meta-analysis.Journal of thoracic disease · 2021Article
- The Sex-Related Interplay between TME and Cancer: On the Critical Role of Estrogen, MicroRNAs and Autophagy.Cancers · 2021Review
- Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC.JTO clinical and research reports · 2021Article
- Expression and clinical implications of estrogen receptors in thoracic malignancies: a narrative review.Journal of thoracic disease · 2021Review
- The prevalence and prognostic significance of estrogen receptor beta expression in non-small cell lung cancer.Translational lung cancer research · 2020Article
- Influence of Estrogen on the NSCLC Microenvironment: A Comprehensive Picture and Clinical Implications.Frontiers in oncology · 2020Review
- Article
- Estrogen receptor-beta is a potential target for triple negative breast cancer treatment.Oncotarget · 2018Article
- Expression of aromatase in tumor related stroma is associated with human bladder cancer progression.Cancer biology & therapy · 2018Article
- Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2018Article
- Estrogen Receptor Beta-Mediated Modulation of Lung Cancer Cell Proliferation by 27-Hydroxycholesterol.Frontiers in endocrinology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
Estrogen signaling pathways may play a significant role in the pathogenesis of non-small cell lung cancers (NSCLC) as evidenced by the expression of aromatase and estrogen receptors (ERα and ERβ) in many of these tumors. Here we examine whether ERα and ERβ levels in conjunction with aromatase define patient groups with respect to survival outcomes and possible treatment regimens. Immunohistochemistry was performed on a high-density tissue microarray with resulting data and clinical information available for 377 patients. Patients were subdivided by gender, age and tumor histology, and survival data was determined using the Cox proportional hazards model and Kaplan-Meier curves. Neither ERα nor ERβ alone was predictor of survival in NSCLC. However, when coupled with aromatase expression, higher ERβ levels predicted worse survival in patients whose tumors expressed higher levels of aromatase. Although this finding was present in patients of both genders, it was especially pronounced in women ≥ 65 years old, where higher expression of both ERβ and aromatase indicated a markedly worse survival rate than that determined by aromatase alone. Expression of ERβ together with aromatase has predictive value for survival in different gender and age subgroups of NSCLC patients. This predictive value is stronger than each individual marker alone. Our results suggest treatment with aromatase inhibitors alone or combined with estrogen receptor modulators may be of benefit in some subpopulations of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.